Overview

A Study of SGN-B6A in Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
This trial will look at a drug called SGN-B6A to find out whether it is safe for people who have solid tumors. It will study SGN-B6A to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SGN-B6A works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-B6A should be given to participants. Part B will use the dose found in Part A to find out how safe SGN-B6A is and if it works to treat solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Seagen Inc.
Seattle Genetics, Inc.